Research indicates that miR-331-3p promotes chemoresistance in pancreatic cancer by activating the Wnt/β-catenin pathway and suppressing the ST7L gene. Often upregulated in patient plasma, this microRNA serves as a potential biomarker for monitoring treatment efficacy. Access the full study via SAGE Journals .
